Advancing Core Product ICVAX® for HIV & Immunotherapy Pipeline for Cancers
HONG KONG SAR –
Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("
Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong.